Tatva Chintan Pharma Chem Past Earnings Performance
Past criteria checks 1/6
Tatva Chintan Pharma Chem's earnings have been declining at an average annual rate of -17.1%, while the Chemicals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 0.7% per year. Tatva Chintan Pharma Chem's return on equity is 3.5%, and it has net margins of 6.8%.
Key information
-17.1%
Earnings growth rate
-20.0%
EPS growth rate
| Chemicals Industry Growth | 17.7% |
| Revenue growth rate | 0.7% |
| Return on equity | 3.5% |
| Net Margin | 6.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11
Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Revenue & Expenses Breakdown
How Tatva Chintan Pharma Chem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3,846 | 261 | 552 | 0 |
| 31 Mar 24 | 3,935 | 304 | 563 | 0 |
| 31 Dec 23 | 4,198 | 377 | 526 | 0 |
| 30 Sep 23 | 4,562 | 459 | 483 | 0 |
| 30 Jun 23 | 4,496 | 452 | 416 | 0 |
| 31 Mar 23 | 4,236 | 455 | 431 | 0 |
| 31 Dec 22 | 3,976 | 460 | 377 | 0 |
| 30 Sep 22 | 3,817 | 572 | 353 | 0 |
| 30 Jun 22 | 4,152 | 825 | 324 | 0 |
| 31 Mar 22 | 4,336 | 959 | 320 | 0 |
| 31 Dec 21 | 4,438 | 995 | 311 | 0 |
| 30 Sep 21 | 4,192 | 976 | 300 | 0 |
| 30 Jun 21 | 3,557 | 687 | 279 | 0 |
| 31 Mar 21 | 3,004 | 523 | 253 | 0 |
| 31 Mar 20 | 2,632 | 378 | 217 | 0 |
| 31 Mar 19 | 2,063 | 205 | 174 | 0 |
| 31 Mar 18 | 1,358 | 123 | 131 | 0 |
Quality Earnings: TATVA has high quality earnings.
Growing Profit Margin: TATVA's current net profit margins (6.8%) are lower than last year (10.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TATVA's earnings have declined by 17.1% per year over the past 5 years.
Accelerating Growth: TATVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TATVA had negative earnings growth (-42.3%) over the past year, making it difficult to compare to the Chemicals industry average (10.7%).
Return on Equity
High ROE: TATVA's Return on Equity (3.5%) is considered low.